Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 378971, 9 pages
http://dx.doi.org/10.1155/2013/378971
Research Article

Intricacies for Posttranslational Tumor-Targeted Cytokine Gene Therapy

1Department of Musculoskeletal Oncology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China
2Department of Pediatrics, UT Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Unit 853, 1515 Holcombe Boulevard, Houston, TX 77030, USA

Received 30 August 2013; Accepted 30 October 2013

Academic Editor: Mohammad Athar

Copyright © 2013 Jeffry Cutrera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y.-J. Ko, G. J. Bubley, R. Weber et al., “Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer,” Journal of Immunotherapy, vol. 27, no. 3, pp. 232–239, 2004. View at Google Scholar · View at Scopus
  2. S. K. Seung, B. Curti, M. Crittenden, and W. Urba, “Radiation and immunotherapy: renewed allies in the war on cancer,” Oncoimmunology, vol. 1, no. 9, pp. 1645–1647, 2012. View at Google Scholar
  3. R. Craig, J. Cutrera, S. Zhu, X. Xia, Y.-H. Lee, and S. Li, “Administering plasmid DNA encoding tumor vessel-anchored IFN-α for localizing gene product within or into tumors,” Molecular Therapy, vol. 16, no. 5, pp. 901–906, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. B. Atkins, M. J. Robertson, M. Gordon et al., “Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies,” Clinical Cancer Research, vol. 3, no. 3, pp. 409–417, 1997. View at Google Scholar · View at Scopus
  5. J. Cutrera, D. Dibra, X. Xia, A. Hasan, S. Reed, and S. Li, “Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy,” Molecular Therapy, vol. 19, no. 8, pp. 1468–1477, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. S. D. Reed, A. Fulmer, J. Buckholz et al., “Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs,” Cancer Gene Therapy, vol. 17, no. 7, pp. 457–464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Robertson, C. Cameron, M. B. Atkins et al., “Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer,” Clinical Cancer Research, vol. 5, no. 1, pp. 9–16, 1999. View at Google Scholar · View at Scopus
  8. M. N. Torrero, X. Xia, W. Henk, S. Yu, and S. Li, “Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression,” Cancer Research, vol. 66, no. 8, pp. 4461–4467, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Chertova, C. Bergamaschi, O. Chertov et al., “Characterization and favorable in vivo properties of heterodimeric soluble IL-15.IL-15 Ralpha cytokine compared to IL-15 monomer,” Journal of Biological Chemistry, vol. 288, no. 25, pp. 18093–18103, 2013. View at Google Scholar
  10. M. Kaspar, E. Trachsel, and D. Neri, “The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis,” Cancer Research, vol. 67, no. 10, pp. 4940–4948, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. R. M. Teague, B. D. Sather, J. A. Sacks et al., “Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors,” Nature Medicine, vol. 12, no. 3, pp. 335–341, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Xu, M. Jones, B. Liu et al., “Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma,” Cancer Research, vol. 73, no. 10, pp. 3075–3086, 2013. View at Google Scholar
  13. G. Lippi and E. J. Favaloro, “Recombinant platelet factor 4: a therapeutic, anti-neoplastic chimera?” Seminars in Thrombosis and Hemostasis, vol. 36, no. 5, pp. 558–569, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Wang and H. Huang, “Platelet factor-4 (CXCL4/PF-4): an angiostatic chemokine for cancer therapy,” Cancer Letters, vol. 331, no. 2, pp. 147–153, 2013. View at Google Scholar
  15. L. Yang, J. Du, J. Hou, H. Jiang, and J. Zou, “Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo,” BMC Cancer, vol. 11, article 261, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. “ClinicalTrials.gov,” 2012, www.ClinicalTrials.gov.
  17. National Cancer Institute, “Biological Therapies for Cancer,” Cancer Fact Sheets, 2013, http://www.cancer.gov/cancertopics/factsheet/Therapy/biological.
  18. A. J. Mellott, M. L. Forrest, and M. S. Detamore, “Physical non-viral gene delivery methods for tissue engineering,” Annals of Biomedical Engineering, vol. 41, no. 3, pp. 446–468, 2013. View at Google Scholar
  19. J. L. Santos, D. Pandita, J. Rodrigues, A. P. Pêgo, P. L. Granja, and H. Tomás, “Non-viral gene delivery to mesenchymal stem cells: methods, strategies and application in bone tissue engineering and regeneration,” Current Gene Therapy, vol. 11, no. 1, pp. 46–57, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Wang, W. Li, N. Ma, and G. Steinhoff, “Non-viral gene delivery methods,” Current Pharmaceutical Biotechnology, vol. 14, no. 1, pp. 46–60, 2013. View at Google Scholar
  21. A. I. Daud, R. C. DeConti, S. Andrews et al., “Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 26, no. 36, pp. 5896–5903, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Jakobisiak, J. Golab, and W. Lasek, “Interleukin 15 as a promising candidate for tumor immunotherapy,” Cytokine and Growth Factor Reviews, vol. 22, no. 2, pp. 99–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Craig and S. Li, “Function and molecular mechanism of tumor-targeted peptides for delivering therapeutic genes and chemical drugs,” Mini-Reviews in Medicinal Chemistry, vol. 6, no. 7, pp. 757–764, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Croft, C. A. Benedict, and C. F. Ware, “Clinical targeting of the TNF and TNFR superfamilies,” Nature Reviews Drug Discovery, vol. 12, no. 2, pp. 147–168, 2013. View at Google Scholar
  25. J. Cutrera and S. Li, “Passive and active tumor homing cytokine therapy,” in Targeted Cancer Immune Therapy, J. Lustgarten, Y. Cui, and S. Li, Eds., pp. 97–113, Springer, New York, NY, USA, 2009. View at Google Scholar
  26. P. Fournier and V. Schirrmacher, “Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future,” BioDrugs, vol. 27, no. 1, pp. 35–53, 2013. View at Google Scholar
  27. A. Satelli and S. Li, “Vimentin in cancer and its potential as a molecular target for cancer therapy,” Cellular and Molecular Life Sciences, vol. 68, no. 18, pp. 3033–3046, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Cutrera, B. Johnson, L. Ellis, and S. Li, “Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: a novel tool for mechanistic and therapeutic studies,” Cancer Letters, vol. 329, no. 1, pp. 68–73, 2013. View at Google Scholar
  29. F. Curnis, A. Gasparri, A. Sacchi, R. Longhi, and A. Corti, “Coupling tumor necrosis factor-α with αV integrin ligands improves its antineoplastic activity,” Cancer Research, vol. 64, no. 2, pp. 565–571, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Colombo, F. Curnis, G. M. S. De Mori et al., “Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif,” Journal of Biological Chemistry, vol. 277, no. 49, pp. 47891–47897, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Corti, F. Curnis, W. Arap, and R. Pasqualini, “The neovasculature homing motif NGR: more than meets the eye,” Blood, vol. 112, no. 7, pp. 2628–2635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Bhatia, M. E. Menezes, S. K. Das et al., “Innovative approaches for enhancing cancer gene therapy,” Discovery Medicine, vol. 15, no. 84, pp. 309–317, 2013. View at Google Scholar
  33. E. Cha and A. Daud, “Plasmid IL-12 electroporation in melanoma,” Human Vaccines and Immunotherapeutics, vol. 8, no. 11, pp. 1734–1738, 2012. View at Google Scholar
  34. L. Heller, K. Merkler, J. Westover et al., “Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model,” Clinical Cancer Research, vol. 12, no. 10, pp. 3177–3183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Park, K. Singha, S. Son et al., “A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy,” Cancer Gene Therapy, vol. 19, no. 11, pp. 741–748, 2012. View at Google Scholar
  36. W. Chen, P. A. Jarzyna, G. A. F. van Tilborg et al., “RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe,” FASEB Journal, vol. 24, no. 6, pp. 1689–1699, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Dehari, Y. Ito, T. Nakamura et al., “Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer,” Cancer Gene Therapy, vol. 10, no. 1, pp. 75–85, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. D. Ma, Y. Chen, L. Fang et al., “Purification and characterization of RGD tumor-homing peptide conjugated human tumor necrosis factor α over-expressed in Escherichia coli,” Journal of Chromatography B, vol. 857, no. 2, pp. 231–239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Okada, N. Okada, H. Mizuguchi et al., “Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma,” Biochimica et Biophysica Acta, vol. 1670, no. 3, pp. 172–180, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Okada, N. Okada, S. Nakagawa et al., “Tumor necrosis factor α-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors,” Japanese Journal of Cancer Research, vol. 93, no. 4, pp. 436–444, 2002. View at Google Scholar · View at Scopus
  41. K. Temming, R. M. Schiffelers, G. Molema, and R. J. Kok, “RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature,” Drug Resistance Updates, vol. 8, no. 6, pp. 381–402, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Wang, K. Chen, W. Cai et al., “Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein,” Molecular Cancer Therapeutics, vol. 7, no. 5, pp. 1044–1053, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Briat, C. H. F. Wenk, M. Ahmadi et al., “Reduction of renal uptake of 111In-DOTA-labeled and A700-labeled RAFT-RGD during integrin αvβ3 targeting using single positron emission computed tomography and optical imaging,” Cancer Science, vol. 103, no. 6, pp. 1105–1110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Sancey, E. Garanger, S. Foillard et al., “Clustering and internalization of integrin αvβ3 with a tetrameric RGD-synthetic peptide,” Molecular Therapy, vol. 17, no. 5, pp. 837–843, 2009. View at Google Scholar
  45. L. Diao and B. Meibohm, “Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides,” Clinical Pharmacokinetics, vol. 52, no. 10, pp. 855–868, 2013. View at Google Scholar